Although methamphetamine remains a problem, new psychoactive substances (NPS) have become an emerging issue in both Taiwan and South Korea, though their patterns differ. Taiwan seizes much larger quantities of NPS, particularly ketamine, despite having far fewer controlled NPS items than Korea. These differences suggest the NPS come from different sources. Factors beyond geographical proximity, including drug policy and drug availability and accessibility, help explain the current status of illegal drug use in the two countries.
International drug policy is changing alongside promising evidence for psychedelic-assisted psychotherapy (PAP) to treat mental health conditions. Canada has expanded therapeutic access, reversing an 8-year ban on medical exemptions through the Special Access Programme in January 2022 and granting the first exemptions for legal possession and personal use of psilocybin mushrooms in 2020, nearly 50 years after criminalization. This piece clarifies factors for safely expanding access to psychedelics. Streamlining safe, evidence-based compassionate use of PAP could offer timely treatment options while encouraging further research and outcome surveillance to refine best practices.